anonymous
Guest
anonymous
Guest
The analysts started scratching their heads during an earnings conference call as there was a lack of clarity in the delay in filing of Biogen's Alzheimer's drug.
Last year, Biogen stock soared by 27% after the company optimistically said it would file an application with the US Food and Drug Administration for the approval of its Alzheimer’s candidate, aducanumab.
You can find what all the analysts asked during the call here and when will the company file the application
Last year, Biogen stock soared by 27% after the company optimistically said it would file an application with the US Food and Drug Administration for the approval of its Alzheimer’s candidate, aducanumab.
You can find what all the analysts asked during the call here and when will the company file the application